Pharmaceutical Technology12 天
Durvalumab by AstraZeneca for Neuroendocrine Carcinoma: Likelihood of Approval
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.
Pharmaceutical Technology12 天
Camrelizumab by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer.